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INTRODUCTION
A pelvic mass is one of the most frequent indications for re­
fe  rral to specialist gynecologists. Often, these pelvic masses 
are malignant and require surgical treatment. Up to 24% of 
ova  rian tumors in premenopausal women are malignant and 
up to 60% are malignant in postmenopausal women [1­3]. 
The preoperative diagnosis of whether a mass is malignant 
cannot always be made with current diagnostic modalities. 
Surgery can be optimally planned if an ovarian neoplasm is 
known to be benign or malignant in advance. The type of 
surgical procedure and the experience of the surgeon are im­
portant factors for the prognosis of ovarian cancer. An impro­
ved method for preoperative discrimination of a pelvic mass 
would result in more women receiving first­line therapy from 
appropriately trained and experienced personnel [4,5]. For 
such referrals to be efficient, improved specific and sensitive 
methods for diagnosing ovarian cancers are needed.
Many investigators have employed a variety of sonographic 
variables in an attempt to predict a malignancy, including 
Doppler analysis [6­12]. A number of articles have discussed 
ovarian tumors and the panel of different tumor markers [13­
16]. Various combined methods for evaluating the risk of ovar­
ian cancer in women have been proposed [17,18]. The risk of 
malignancy index (RMI) is a simple scoring system based on 
menopausal status, ultrasound, and serum concentrations 
Original Article
Comparison of four malignancy risk indices in the 
detection of malignant ovarian masses
Erhan Aktürk, Rıza Efendi Karaca, İbrahim Alanbay, Murat Dede, Emre Karaşahin, Müfit Cemal Yenen, 
İskender Başer
Obstetrics and Gynecology Department, Gulhane Military Medicine Academy, Ankara, Turkey
Received Dec 24, 2010, Revised Jan 22, 2011, Accepted Feb 21, 2011
Correspondence to Erhan Aktürk 
Obstetrics and Gynecology Department, Gülhane Military Medicine 
Academy, Etlik 06010 Keçiören, Ankara, Turkey. Tel: 90-5324835262, Fax: 90-
3123045800, E-mail: erhnakturk@gmail.com
pISSN 2005-0380
eISSN 2005-0399
Copyright © 2011. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology and Colposcopy 
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and 
reproduction in any medium, provided the original work is properly cited.
www.ejgo.org
Objective: The aim of this study was to evaluate the ability of four risk of malignancy indices (RMI) to detect malignant ovarian 
tumors.
Methods: This is a prospective study of 100 women admitted to the Department of Obstetrics and Gynecology of Gulhane Mili­
tary Medicine Academy for surgical exploration of pelvic masses. To diagnose malignant ovarian tumors, the sensitivity, speci  fi­
city, negative and positive predictive values and diagnostic accuracy of four RMIs (RMI 1, RMI 2, RMI 3, and RMI 4) were obtained.
Results: In our study we found that there is no statistically significant difference in the performance of four different RMIs in 
discriminating malignancy. We think that malignancy risk indices is more reliable than the menopausal status, serum CA­125 
levels, ultrasound features and tumor size separately in detecting malignancy.
Conclusion: We concluded that any of the four malignancy risk indices described can be used for selection of cases for optimal 
the  rapy. These methods are simple techniques that can be used even in less­specialized gynecology clinics to facilitate the 
selec  tion of cases for referral to an oncological unit.
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of CA­125. This has given much better results than a single 
parameter [18­23]. The RMI can be applied in less specialized 
centers. The risk of malignancy index is the product of the 
ultrasound scores (U), the menopausal score (M), and the ab­
solute value of serum CA­125 levels: RMI = U x M x CA­125.
In the 1990s, Jacobs et al. [18] originally developed the RMI, 
which is now termed RMI 1. Tingulstad et al. [19] developed 
their version of the RMI in 1996 and it is known as RMI 2. In 
1999, Tingulstad et al. [20] modified the RMI, which is termed 
RMI 3. Yamamoto et al. [24] created their own model of a ma­
lignancy risk index. They added the parameter of the tumor 
size (S) to the RMI and have termed it the RMI 4.
The purpose of this study was to evaluate the ability of the 
four malignancy risk indices to discriminate a benign from a 
malignant pelvic mass and to evaluate the performances of 
the four malignancy risk indices.
MATERIALS AND METHODS
The clinical data of 100 women with pelvic masses ap­
pointed for laparotomy or laparoscopy between October 1, 
2008, and February 3, 2010, to our hospital were obtained. We 
began our trial to compare RMI 1, RMI 2, and RMI 3 with each 
other. During the data collection period, in 2009, Yamomoto 
et al. [24] published their study about RMI 4. So we calculated 
RMI 4 scores of masses retrospectively before 2009 and pro­
spectively after that year. Preoperative serum CA­125 levels, 
ultrasound findings, and menopausal status were noted. The 
ultrasound was performed transvaginally by a 7.5­MHz trans­
ducer (Siemens, Antares Sonoline, CA, USA). A transabdominal 
repeat examination with a full bladder was obtained if a mass 
was found to be too large to be observed completely trans­
vaginally. A score was assigned for the following ultrasound 
features suggestive of malignancy: the presence of a multi­
locular cystic lesion, solid areas, bilateral lesions, ascites, and 
intraabdominal metastases, scored as one point for each. A 
total ultrasound score (U) was thus calculated for each patient. 
Tumor size (S) was measured by ultrasound for each patient. 
Postmenopausal status was defined as more than 1 year of 
amenorrhea or age older than 50 years in women who had 
undergone hysterectomy. All other women were considered 
premenopausal. Serum samples were collected preoperatively 
and serum CA­125 levels were measured using Electrochemi­
luminescence Immunoassaay (ECLIA) (Roche Elecsys E 170­1) 
in accordance with the manufacturer’s instructions. Based on 
the data obtained, RMI 1, RMI 2, RMI 3, and RMI 4 were calcu­
lated for all patients together with the sensitivity, specificity, 
diagnostic accuracy and positive and negative predictive val­
ues of the four methods as follows:
1. RMI 1 (Jacobs et al. 1990) = U x M x CA­125, where a total 
ultrasound score of 0 made U=0, a score of 1 made U=1, 
and a score of ≥2 made U=3; premenopausal status made 
M=1 and postmenopausal M=3. The serum level of CA­
125 was applied directly to the calculation [18].
2. RMI 2 (Tingulstad et al. 1996) = U x M x CA­125, where a 
total ultrasound score of 0 or 1 made U=1, and a score of 
≥2 made U=4; premenopausal status made M=1 and post­
menopausal M=4. The serum level of CA­125 was applied 
directly to the calculation [19].
3. RMI 3 (Tingulstad et al. 1999) = U x M x CA­125, where a 
total ultrasound score of 0 or 1 made U=1, and a score of 
≥2 made U=3; premenopausal status made M=1 and post­
menopausal M=3. The serum level of CA­125 was applied 
directly to the calculation [20].
4. RMI 4 (Yamamoto et al. 2009) = U x M x S (size in centime­
ters) x CA­125, where a total ultrasound score of 0 or 1 
made U=1, and a score of ≥2 made U=4. Premenopausal 
status made M=1 and postmenopausal status made M=4. 
A tumor size (single greatest diameter) of <7 cm made 
S=1, and ≥7 cm made S=2. The serum level of CA­125 was 
applied directly to the calculation [24].
The histopathological diagnosis was considered as the gold 
standard for definite outcome. We did not include borderline 
tumors in our study. When a gynecological cancer was found, 
it was staged according to the International Federation of 
Gynecology and Obstetrics classification [21]. All statistical 
analyses were performed using the SPSS ver. 15.0 (SPSS Inc., 
Chicago, IL, USA). The x² test was used to test differences in 
distribution of age, menopausal status, and ultrasound score. 
The Mann­Whitney U­test was applied when testing differ­
ences in distribution of CA­125 among women with benign 
and malignant pelvic masses. The McNemar’s test was used 
when testing differences in performances between RMI 1, RMI 
2, RMI 3, and RMI 4. The sensitivity was defined as the percent­
age of patients with malignant disease having a positive test 
result. The specificity was defined as the percentage with 
benign disease having a negative test result. The positive pre­
dictive value was defined as the percentage of patients with a 
positive test result having malignant disease and the negative 
predictive value was defined as the percentage of patients 
with a negative test result having benign disease.
RESULTS
As a result of the histological examination of the surgical 
spe  ci  mens of 100 patients, 80 (80%) had benign and 20 (20%) Risk of malignancy indices for detection of ovarian cancer
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had malignant disease (Table 1). The histopathological clas­
sification of all cases and the stage distribution of malignant 
ones are given in Table 1. The distribution of benign and 
malignant cases by age, menopausal status, tumor size and 
ultrasound score is described in Table 2. In univariate analysis 
a significant linear trend for malignancy was found by increas­
ing ultrasound score and the occurrence of malignancy in the 
pre­ and postmenopausal patients. Although the risk of ma­
lignancy was increasing by age, it did not reach the statistical 
significance (p=0.051). 
The mean serum level of CA­125 was significantly higher 
among women with malignancy when compared with 
women with benign tumors (329.2310 U/mL vs. 28.0374 U/
mL). The sensitivity, specificity, and positive and negative pre­
dictive values and diagnostic accuracy of serum CA­125 level 
of 35 U/mL, the ultrasound score of 2, postmenopausal status 
and the size of 7 centimeters are reported in Table 3. When 
individual parameters were compared in Table 3, CA­125 had 
better sensitivity than the ultrasound score, size and meno­
pausal status, even though the others had higher specificity  Table 1. Histopathological clasification and stage distribution of cases
Histological diagnosis No. (%)
Ovarian cancer
  Stage I 12 (60)
  Stage II  2 (10)
  Stage III  4 (20)
  Stage IV   2 (10)
Total malignant cases  20 (20)
  Serous cystadenocarcinoma   8
  Mucinous cystadenocarcinoma  10
  Ovarian lymphoma  1
  Krukenberg’s tumor  1
Total benign cases 80 (80)
  Simple cyst  5
  Endometriosis  27
  Dermoid cyst   14
  Serous cystadenoma  8
  Mucinous cystadenoma   7
  Fibroma  3
  Tekoma  2
  Corpus luteum  4
  Paratubal cyst  5
  Leiomyoma   2
  Struma ovarii   1
  Tuboovarian abcess  2
Table 2. The distribution of benign and malignant cases by age, me­
no  pausal status, serum CA­125, tumor size and ultrasound score
Variables Benign Malignant Test/p­value
Age (yr) х²/0.051
  <20 6 1
  21­40 34 4
  41­50 28 5
  >50 12 10
Menopausal status х²/0.002
  Premenopausal 64 9
  Postmenopausal 16 11
Ultrasound score х²/<0.001
  0 50 3
  1 19 6
  2­5 11 11
CA­125 (U/mL) U test/<0.001
  Mean 28.0374 329.2310
  Minimum 3.14 12
  Maximum 120 2,821
Standard deviation 23.75577 648.0259
Size (cm) х²/<0.002
  <7  68 7
  ≥7  12 13
Table 3. The sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values and diagnostic accuracy (DA) of serum CA­125, 
ultrasound score, postmenopausal status and tumor size
Criteria Sensitivity  (%) Specificity (%) PPV (%) NPV (%) DA (%)
CA­125
  35 U/mL 75 75 92.3 42.9 75
Ultrasound score
  ≥2 55 86.3 88.5 50 80
Menopausal status
  Postmenopausal 55 80 87.7 40.7 75
Tumor size
  ≥7 cm 65 85 90.7 52 81Erhan Aktürk, et al.
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than CA­125, but with considerable loss of sensitivity which 
is important in suspecting a malignancy. The performance 
of RMI 1, RMI 2, RMI 3, and RMI 4 at different cutoff values is 
shown in Table 4. The overall best performance in RMI 1, RMI 2, 
and RMI 3 was obtained at a cutoff level of 200 and at 500 for 
RMI 4. Although, at a cutoff level of 200 for RMI 1, RMI 2, RMI 3, 
and at the level of 450 for RMI 4, RMI 4 looked like better than 
the others with its sensitivity, specificity and the diagnostic 
accuracy rates, direct comparison of the four indices revealed 
that there was no statistically significant difference in per­
formance of the four methods (McNemar test, p=0.063 ). Re­
ceiver operating characteristic (ROC) analysis of the RMI 1, RMI 
2, RMI 3, and RMI 4 showed that the values of area under the 
curve were significantly high with a value of 0.825, 0.806, 0.825, 
0.856, respectively (p<0.001). Area under the curves values 
of menopausal status, serum CA­125, US features, and tumor 
size are 0.675, 0.750, 0.706, and 0.750, respectively. We think 
that risk of malignancy indices were more reliable in detecting 
malignancy in terms of area under the curves. The diagnostic 
performance of ultrasound score, CA­125, menopausal sta­
tus, tumor size, RMI 1, RMI 2, RMI 3, and RMI 4 is shown in the 
receiver­operating characteristic curves (Fig. 1). 
DISCUSSION
This study has revealed the usefulness of RMI to correctly dis­
criminate benign from malignant pelvic masses. The RMI was 
Table 4. Sensitivity, specificity, positive (PPV) and negative (NPV) predictive values, and diagnostic accuracy (DA) for detecting malignancy at 
different cutoff levels of RMI 1, RMI 2, RMI 3, and RMI 4 
Cutoff Sensitivity Specificity PPV (%) NPV (%) DA (%)
RMI 
1,2,3
RMI 
4
RMI 
1
RMI 
2
RMI 
3
RMI 
4
RMI 
1
RMI 
2
RMI 
3
RMI 
4
RMI 
1
RMI 
2
RMI 
3
RMI 
4
RMI 
1
RMI 
2
RMI 
3
RMI 
4
RMI 
1
RMI 
2
RMI 
3
RMI 
4
  50 350 85 90 90 85 59 69 72 85 35 42 44 51 94 96 96 95 64 73 75 81
100 400 75 85 80 85 84 80 83 85 53 51 53 58 93 95 94 95 82 81 82 85
150 450 75 75 75 84 85 84 85 87 55 53 55 60 93 93 93 95 83 82 83 86
200 500 75 75 75 85 89 85 87 88 62 55 57 63 93 93 93 95 86 83 84 87
250 550 65 75 70 70 95 87 94 90 76 57 73 63 91 93 92 92 89 84 89 86
300 600 45 70 55 60 97 92 98 93 75 66 84 66 87 92 89 90 86 87 89 86
350 650 45 55 50 60 98 96 99 94 82 78 91 70 87 89 88 90 87 87 89 87
400 700 30 50 30 50 98 97 99 98 75 77 85 83 85 88 85 88 84 87 84 88
RMI, risk of malignancy index.
Fig. 1. Receiver operator characteristic 
curve showing the perfor  mance of RMI 1, 
RMI 2, RMI 3, RMI 4, CA­125, tumor size, 
ultrasound score, and menopausal status. 
RMI, risk of malignancy index.Risk of malignancy indices for detection of ovarian cancer
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originally developed by Jacobs et al. [18], and subsequently 
the same group reproduced the results in a second patient 
group, establishing the superiority of RMI over the individual 
parameters [22]. 
In our patient group we found that there is no statistically 
significant difference in the performance of these four differ­
ent malignancy risk indices (RMI 1, RMI 2, RMI 3, and RMI 4) in 
discriminating malignancy. But RMI 2 was found to be more 
reliable in discriminating benign and malignant disease by 
other investigators [19,23]. Tingulstad et al. [19] developed 
their RMI in 1996 and called it RMI 2. They compared it with 
that established by Jacobs et al. [18] and found that at a cutoff 
level of 200, a direct comparison of the two indices showed 
that RMI 2 was significantly better than RMI 1 (McNemar test, 
p=0.001). Morgante et al. [23] also found a similar result that 
for all cutoff values between 80 and 250, RMI 2 performed 
better than RMI 1 (p=0.0001). Tingulstad et al. [20] modified 
the RMI and defined it RMI 3, and they observed that at a cut­
off level of 200 the sensitivity and specificity were 71 and 92%, 
respectively. 
In 2001 Manjunath et al. [25] compared RMI 1, RMI 2, and 
RMI 3 with each other and also confirmed that there was no 
statistical difference between these three indices in benign 
­ malignancy discrimination. In their study, Clarke et al. [26], 
using a cut­off of 120, found that RMI 1 had a sensitivity of 
72% and a specificity of 87%; RMI 2 had a sensitivity of 76% 
and a specificity of 81%; RMI 3 had a sensitivity of 74% and 
a specificity of 84%. In 2009 Yamamoto et al. [24] developed 
their own RMI by using tumor size and called it RMI 4. Their 
study confirms that, at a cutoff level of 450, the accuracy of 
the RMI 4 was better than RMI 1 (p=0.0013), RMI 2 (p=0.0009) 
and RMI 3 (p=0.0013) with a cutoff level of 200. They observed 
that at a cutoff level of 450 the sensitivity, specificity, positive 
predictive value, negative predictive value and accuracy were 
respectively, 86.8%, 91.0%, 63.5%, 97.5%, and 90.4% [24]. In 
our study we found a sensitivity, specificity, positive predictive 
value, negative predictive value and accuracy of 85%, 87%, 
60%, 95%, and 86%, respectively, which is comparable with 
the results of Yamamoto et al. [24]. But we also found that the 
other three indices’ diagnostic performances were reliable, 
being different than Yamomoto et al’s results. 
The risk of malignancy index is a simple scoring system, ap­
pears to be very accurate, is useful in clinical practice, and 
should therefore be the test of choice in the preoperative 
evaluation of the adnexal mass. Any of the four malignancy 
risk indices (RMI 1, RMI 2, RMI 3, RMI 4) described can be used 
for selection of cases for optimal therapy. Since the specific­
ity of risk of malignancy index is high, there is a potential role 
for this index in the selection of cases for conservative man­
agement or minimal invasive surgery of benign cases, like 
ultrasound guided aspiration or laparoscopic excision of other 
cysts. 
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